NCT01216085View on ClinicalTrials.gov

An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
CMLImatinib
Interventions
DRUG

high-dose imatinib

Study patients will receive 400 mg twice daily oral administration in the morning and the evening.

Trial Locations (1)

01008

Novartis Investigational Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY